Eliem Therapeutics, Inc. (ELYM)
Chart Events
Performance Outlook
| Previous Close | 2.6200 |
| Open | 2.6400 |
| Bid | 2.5700 x 800 |
| Ask | 2.6300 x 1100 |
| Day's Range | 2.6000 - 2.7300 |
| 52 Week Range | 2.2100 - 4.7500 |
| Volume | |
| Avg. Volume | 34,298 |
| Market Cap | 71.245M |
| Beta (5Y Monthly) | 0.47 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7000 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.50 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ELYM
Related Research
- Eliem Therapeutics, IncDaily – Vickers Top Buyers & Sellers for 08/18/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat2 years agoArgus Research
Simply Wall St.Eliem Therapeutics (NASDAQ:ELYM) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
ZacksEliem (ELYM) to Explore Strategic Options, Stock Rises 6%
Eliem (ELYM) announces its decision to halt its Kv7 development program in its quest to explore strategic alternatives. The stock of the company rises 6% in response on Thursday.
GlobeNewswireEliem Therapeutics Announces Plans to Explore Strategic Alternatives
SEATTLE and CAMBRIDGE, United Kingdom, July 20, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities, and has made the determination to halt further development of its Kv7 program and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value. Eliem has engaged Leerink Partners to act as a strategic advisor in
